

## Corporate Profile

### Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for dialysis, a blood-filtering therapy replacing vital kidney functions for patients suffering from chronic kidney failure. Through its network of more than 3,200 dialysis clinics in over 40 countries, Fresenius Medical Care provides dialysis treatments to around 264,000 patients. With more than 40 production sites around the globe, the company is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

## Strategy

Our long-term strategy aims at sustainably increasing shareholder value. We focus our business activities on our patients' health and hence on the quality of treatment with the objective of improving their quality of life and raising their life expectancy.

As our previous growth strategy GOAL 13 comes to a close in 2013, we intend to set new goals in the current financial year that will allow us to maintain our outstanding market position and to be successful in the dialysis market. Basically we will continue along our growth paths in the future:

- Organic growth through expansion of our clinic network, initiation of innovative dialysis products and comprehensive treatment concepts,
- acquisitions, with focus on particularly attractive regions,
- horizontal expansion and a boosted activity in home therapies


## Key figures - summary second quarter 2013

Net revenue	\$ 3,613 million	+5%
Operating income (EBIT), adjusted	\$ 555 million	-2%
Net income <sup>1</sup> , adjusted	\$ 272 million	+2%
Earnings per share, adjusted	\$ 0.89	+2%
Total assets <sup>2</sup>	\$ 22,328 million	
Operating cash flow	\$ 525 million	+16%

### Goals for 2013

Net revenue	> \$14.6 billion
Net income <sup>1</sup>	\$1.1 billion – \$1.15 billion
Leverage ratio (Debt/EBITDA)	≤ 3.0
Capital expenditures	~ \$700 million
Acquisitions	~ \$500 million

### Revenue second quarter 2013 per region (US\$ 3,613 m)



## Management Board

- Rice Powell (Chairman)
- Michael Brosnan
- Roberto Fusté
- Dr. Emanuele Gatti
- Ron Kuerbitz
- Dr. Rainer Runte
- Dr. Olaf Schermeier
- Kent Wanzek

## Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Dr. Walter L. Weisman
- Rolf A. Classon
- William P. Johnston
- Prof. Dr. Bernd Fahrholz

<sup>1</sup> attributable to shareholders of Fresenius Medical Care AG & Co. KGaA  
<sup>2</sup> as of June 30, 2013



**Share Profile – Key Data**

**Ticker Symbols**

	Ordinary shares
Frankfurt Stock Exchange	FME
New York Stock Exchange (NYSE)	FMS
Reuters: XETRA / Frankfurt Stock Exchange	FMEG.DE / FMEG.F
Bloomberg	FME GY

**Security Identification Numbers**

WKN	578 580
ISIN	DE 0005785802
CUSIP No. (NYSE)	358029106

**Financing Instruments and Maturity Profile**

	Amount in million	Coupon %	Maturity
Credit Agreement Revolver	~\$ 1,250		October 30, 2017
Credit Agreement Term Loan A	\$ 2,600 <sup>1</sup>		October 30, 2017
Senior Notes 2010 - 2016	€ 250	5.50%	July 15, 2016
Senior Notes 2011 - 2016	€ 100	3-month-Euribor +3.50%	Oct. 15, 2016
Senior Notes 2007 - 2017	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2018	\$ 400	6.50%	September 15, 2018
Senior Notes 2011 - 2018	€ 400	6.50%	September 15, 2018
Senior Notes 2012 - 2019	\$ 800	5.625%	July 31, 2019
Senior Notes 2012 - 2019	€ 250	5.25%	July 31, 2019
Senior Notes 2011 - 2021	\$ 650	5.75%	February 15, 2021
Senior Notes 2011 - 2021	€ 300	5.25%	February 15, 2021
Senior Notes 2012 - 2022	\$ 700	5.875%	January 31, 2022
Notes (Schuldscheindarlehen) 2009 - 2014	€ 45 <sup>1</sup>		October 27, 2014
Accounts Receivable Facility	\$ 800		July 31, 2014

**Share price - last 12 months (in €)**




**Financial Calendar**

Event	Date
<b>Report on second quarter 2013:</b>	
Quarterly Report:	August 30, 2013
<b>Report on third quarter 2013:</b>	
Earnings Release/Conference Call:	November 5, 2013
Quarterly Report:	November 29, 2013
<b>Report on full year 2013</b>	
Earnings Release/Conference Call:	February 25, 2014
Analyst meeting:	February 25, 2013

**Capital Structure**

**Overview**



Data as per July 31, 2013

**Contacts**

Fresenius Medical Care AG & Co. KGaA  
Investor Relations & Corporate Communications  
Else-Kröner-Straße 1 61352 Bad Homburg

**Oliver Maier** P: +49(0)6172-609-2525  
Senior Vice President, F: +49(0)6172-609-2301  
Head of IR & CC

**Gerrit Jost** P: +49(0)6172-609-5216  
Vice President

*North America*

**Terry L. Morris** P: +1-800-948-2538  
Vice President F: +1-615-345-5605

<sup>1</sup> at the beginning before amortisation